Radiation Therapy News and Research RSS Feed - Radiation Therapy News and Research

Radiation therapy (also called radiotherapy, x-ray therapy, or irradiation) is the use of a certain type of energy (called ionizing radiation) to kill cancer cells and shrink tumors. Radiation therapy injures or destroys cells in the area being treated (the “target tissue”) by damaging their genetic material, making it impossible for these cells to continue to grow and divide. Although radiation damages both cancer cells and normal cells, most normal cells can recover from the effects of radiation and function properly. The goal of radiation therapy is to damage as many cancer cells as possible, while limiting harm to nearby healthy tissue.
New nationwide survey shows steady increase in pediatric patients treated with proton radiation therapy

New nationwide survey shows steady increase in pediatric patients treated with proton radiation therapy

Results from a new nationwide survey announced today indicate a steady increase in the number of pediatric patients who are being treated with proton radiation therapy for cancerous and non-cancerous tumors. [More]
Esophageal cancer patients treated with proton therapy experience less toxic side effects

Esophageal cancer patients treated with proton therapy experience less toxic side effects

New research by scientists at the University of Maryland School of Medicine has found that esophageal cancer patients treated with proton therapy experienced significantly less toxic side effects than patients treated with older radiation therapies. [More]
Merus Labs International acquires rights to manufacture, market specialty pharmaceutical products in multiple countries

Merus Labs International acquires rights to manufacture, market specialty pharmaceutical products in multiple countries

Merus Labs International Inc. is pleased to announce that one of its wholly owned subsidiaries has signed a definitive agreement to acquire the rights to manufacture, market, and sell two established specialty pharmaceutical products in certain European and other markets. [More]
Scripps Proton Therapy Center reports exceptional results in treating patients with pencil-beam scanning

Scripps Proton Therapy Center reports exceptional results in treating patients with pencil-beam scanning

The nation's first and only proton therapy center to treat patients exclusively with pencil-beam scanning is reporting exceptional results in delivering cancer treatment since opening for patient care just more than a year ago. [More]
Stereotactic body radiotherapy appears to be safe, effective for some pancreatic cancer patients

Stereotactic body radiotherapy appears to be safe, effective for some pancreatic cancer patients

Two studies from Johns Hopkins Kimmel Cancer Center researchers add to preliminary evidence that high-dose radiation treatment, called stereotactic body radiotherapy, appears to be safe and as effective as standard radiation treatment for certain patients with pancreatic cancer whose tumors are advanced but have not spread. [More]
Johns Hopkins researchers identify new therapy to treat lung cancer

Johns Hopkins researchers identify new therapy to treat lung cancer

A multidisciplinary team led by Johns Hopkins researcher Venu Raman, Ph.D., with notable contributions from Guus Bol, Farhad Vesuna and Phuoc Tran of Johns Hopkins, has identified a new therapy for lung cancer, the most common cancer worldwide. The therapy has been in development for six years and involves a first-in-class molecule designed by the team. [More]
Scientists identify new molecules that destroy cancer cells, save healthy ones

Scientists identify new molecules that destroy cancer cells, save healthy ones

Researchers have identified new molecules that kill cancer cells while protecting healthy cells and that could be used to treat a variety of different cancers. The research shines a light on what happens to cells at the moment they become cancerous. [More]
Prostate cancer patients can experience cognitive impairment following androgen deprivation therapy

Prostate cancer patients can experience cognitive impairment following androgen deprivation therapy

Cognitive impairment can occur in cancer patients who are treated with a variety of therapies, including radiation therapy, hormone therapy, and chemotherapy. [More]
Prostate cancer patients who receive androgen deprivation therapy may experience cognitive problems

Prostate cancer patients who receive androgen deprivation therapy may experience cognitive problems

Cognitive impairment can occur in cancer patients who are treated with a variety of therapies, including radiation therapy, hormone therapy, and chemotherapy. After chemotherapy treatment it is commonly called "chemo brain." Signs of cognitive impairment include forgetfulness, inability to concentrate, problems recalling information, trouble multi-tasking and becoming slower at processing information. [More]
Study: Disrupting cancer pathway could extend benefits of new immunity-boosting drugs

Study: Disrupting cancer pathway could extend benefits of new immunity-boosting drugs

Understanding how to overrule a signaling pathway that can cause treatments to fail in metastatic melanoma patients should help physicians extend the benefits of recently approved immunity-boosting drugs known as checkpoint inhibitors to more patients. [More]
Study analyzes outcomes of brain metastases patients following stereotactic radiosurgery

Study analyzes outcomes of brain metastases patients following stereotactic radiosurgery

Winner of the Leksell Radiosurgery Award, Deborah C. Marshall, recently presented her research, Survival Patterns of Patients with Cerebral Metastases after Multiple Rounds of Stereotactic Radiosurgery (SRS), at the 2015 American Association of Neurological Surgeons Annual Scientific Meeting. [More]
Elekta striving to build radiation therapy infrastructures and save lives of cancer patients in Africa

Elekta striving to build radiation therapy infrastructures and save lives of cancer patients in Africa

In Africa, cancer kills more people than HIV/AIDS, malaria and tuberculosis combined. Approximately 40 percent of cancer cases can be prevented and 40 percent can be cured with the right treatment. Together with Elekta, ministries of health in almost a dozen African nations are working to build up their radiation therapy infrastructures and save lives. [More]
Moderate exercise on a regular basis may improve cancer treatments

Moderate exercise on a regular basis may improve cancer treatments

Kansas State University kinesiology research offers encouraging information for cancer patients: A brisk walk or a slow jog on a regular basis may be the key to improved cancer treatments. [More]
OncoGenex provides update on Phase 3 ENSPIRIT trial evaluating custirsen for treatment of NSCLC

OncoGenex provides update on Phase 3 ENSPIRIT trial evaluating custirsen for treatment of NSCLC

OncoGenex Pharmaceuticals, Inc. announced today it has filed an amendment with the U.S. Food and Drug Administration, as well as initiated filing with regulatory agencies in other countries, to amend the statistical design and analysis plan of its pivotal, international Phase 3 ENSPIRIT trial evaluating custirsen in the treatment of non-small cell lung cancer (NSCLC). [More]
OncoGenex terminates agreement with Teva, regains rights to custirsen

OncoGenex terminates agreement with Teva, regains rights to custirsen

OncoGenex Pharmaceuticals, Inc. today announced that its wholly owned subsidiary, OncoGenex Technologies Inc., executed a termination agreement with Teva Pharmaceuticals Ltd. under which OncoGenex will regain rights to custirsen, an investigational compound currently in Phase 3 clinical development as a treatment for prostate and lung cancers. [More]
Men who receive brachytherapy more likely to be cancer-free five years later

Men who receive brachytherapy more likely to be cancer-free five years later

Results from a randomised controlled trial to compare the use of permanent radioactive implants (brachytherapy) with dose-escalated external beam radiotherapy in patients with prostate cancer show that the men who received brachytherapy were twice as likely to be cancer-free five years later. [More]
Increasing radiotherapy can significantly improve survival for children with intracranial ependymoma

Increasing radiotherapy can significantly improve survival for children with intracranial ependymoma

Two studies to be presented today (Sunday) at the 3rd ESTRO Forum in Barcelona, Spain, show that increasing the dose of radiotherapy given to children with an intracranial ependymoma, a form of cancer of the central nervous system, can significantly improve their survival. [More]
Brachytherapy improves overall survival for women with inoperable early stage endometrial cancer

Brachytherapy improves overall survival for women with inoperable early stage endometrial cancer

Women who have early stage endometrial cancer and are inoperable tend to live longer if they have been treated with brachytherapy with or without external beam radiation, according to new research to be presented at the 3rd ESTRO Forum in Barcelona, Spain, on Sunday. [More]
Elekta introduces new Leksell Gamma Knife Icon to treat patients with brain disease

Elekta introduces new Leksell Gamma Knife Icon to treat patients with brain disease

With the introduction of Elekta's new Leksell Gamma Knife Icon, the benefits of precision cranial radiosurgery are now available for more patients with a wider variety of tumor types and sizes. [More]
iCAD announces adoption of Xoft Axxent Electronic Brachytherapy System in Spain

iCAD announces adoption of Xoft Axxent Electronic Brachytherapy System in Spain

iCAD, Inc., an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced the first Xoft Axxent Electronic Brachytherapy (eBx) System in Spain is now available at the Hospital Miguel Servet for the treatment of early-stage breast cancer, non-melanoma skin cancer and gynecological cancers. [More]
Advertisement
Advertisement